Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 14/20 | 0.74 |
| ▸ | JAK2 | O60674 | 11/20 | 0.74 |
| ▸ | TYK2 | P29597 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22580220 | 0.95 | JAK1 (0.74) | JAK1JAK2TYK2 | |
| SCHEMBL29724882 | 0.95 | JAK1 (0.74) | JAK1JAK2TYK2 | |
| SCHEMBL22580197 | 0.92 | JAK1 (0.73) | JAK1JAK2TYK2 | |
| SCHEMBL28930144 | 0.92 | JAK1 (0.73) | JAK1JAK2TYK2 | |
| SCHEMBL29725076 | 0.92 | JAK1 (0.73) | JAK1JAK2TYK2 | |
| SCHEMBL22580118 | 0.92 | JAK1 (0.73) | JAK1JAK2TYK2 | |
| SCHEMBL29725036 | 0.92 | JAK1 (0.73) | JAK1JAK2TYK2 | |
| SCHEMBL29724850 | 0.91 | JAK1 (0.74) | JAK1JAK2TYK2 | |
| SCHEMBL22580154 | 0.91 | JAK1 (0.74) | JAK1JAK2TYK2 | |
| SCHEMBL28665895 | 0.91 | JAK1 (0.74) | JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3956322-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885TYK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.